Astrazeneca, Johnson & Johnson Covid Vaccine Trials Back On Track In US

AstraZeneca Plc has resumed the US trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.

The news signaled progress against the novel coronavirus that has infected more than 41 million globally, including 8 million Americans and comes 10 days before a US presidential election that may hinge on plans to fight the pandemic.

AstraZeneca, one of the leading vaccine developers, had paused its US trial on September 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial.